Home › Funds › PERCEPTIVE ADVISORS LLC › ASND
PERCEPTIVE ADVISORS LLC position in ASND
ASCENDIS PHARMA A/S · Health Care
PERCEPTIVE ADVISORS LLC reported holding 1,163,721 shares of ASND (ASCENDIS PHARMA A/S) in its Q2 2026 13F filing — a position valued at US$310.4M, representing 4.92% of its reported portfolio and ranking #3 among its reported holdings. PERCEPTIVE ADVISORS LLC has disclosed ASND holdings in 6 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How PERCEPTIVE ADVISORS LLC's ASND position evolved
PERCEPTIVE ADVISORS LLC first disclosed a stake in ASND in Q4 2023 at 132,176 shares (US$16.6M). The position peaked in Q1 2026 at 1,531,421 shares, worth US$350.3M. Across 6 filings, PERCEPTIVE ADVISORS LLC increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,163,721 shares valued at US$310.4M — a reduction of -367,700 shares quarter over quarter.. Notable position changes include a 42% increase in Q1 2026 (shares rose 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 132.18K | $16.65M | New |
| Q2 2025 | 963.89K | $166.37M | New |
| Q3 2025 | 1.09M | $216.40M | Add |
| Q4 2025 | 1.08M | $230.60M | Reduce |
| Q1 2026 | 1.53M | $350.28M | Add |
| Q2 2026 | 1.16M | $310.39M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ASND and 13F data
ASND (ASCENDIS PHARMA A/S) is a Health Care company. 42 other funds we track also report a position in ASND — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$2.74B), T. Rowe Price Investment Management, Inc. (US$1.80B), Avoro Capital Advisors LLC (US$1.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ASND
- RA CAPITAL MANAGEMENT, L.P. 10.28M sh · $2.74B · Q2 2026
- T. Rowe Price Investment Management, Inc. 6.75M sh · $1.80B · Q2 2026
- Avoro Capital Advisors LLC 5.11M sh · $1.36B · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 4.80M sh · $1.28B · Q2 2026
- Jupiter Topco LLC 3.65M sh · $973.38M · Q2 2026
- Artisan Partners Limited Partnership 2.63M sh · $702.55M · Q2 2026
- Vestal Point Capital, LP 375.00K sh · $100.02M · Q2 2026
- Tri Locum Partners LP 258.74K sh · $69.01M · Q2 2026
- ORBIMED ADVISORS LLC 244.46K sh · $65.20M · Q2 2026
- PFM Health Sciences, LP 233.17K sh · $62.19M · Q2 2026
- Frazier Life Sciences Management, L.P. 225.16K sh · $60.05M · Q2 2026
- Spyglass Capital Management LLC 215.40K sh · $57.45M · Q2 2026
More on PERCEPTIVE ADVISORS LLC
FAQ
How long has PERCEPTIVE ADVISORS LLC held ASND?
PERCEPTIVE ADVISORS LLC has disclosed ASND holdings in 6 of the last 11 reported quarters, going back to Q4 2023.
What is PERCEPTIVE ADVISORS LLC's current position in ASND?
As of Q2 2026, PERCEPTIVE ADVISORS LLC holds 1.16M shares of ASND (ASCENDIS PHARMA A/S), valued at $310.39M, representing 4.92% of its reported portfolio and ranking #3.
Has PERCEPTIVE ADVISORS LLC been buying or selling ASND?
In the latest 13F filing (Q2 2026), PERCEPTIVE ADVISORS LLC reduced its position in ASND. The position peaked in Q1 2026 at 1.53M shares.
Which other funds hold ASND?
Other major institutional holders of ASND include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.